NNZ-2591
NNZ-2591 is a pharmaceutical drug with 7 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
4
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
2
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
Clinical Trials (7)
An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7